Catalog No.
DHH02209
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
1.3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-936558, MDX-1106, ONO-4538, CAS: 946414-94-4
Clone ID
Nivolumab
Nivolumab for the treatment of colorectal cancer, PMID: 29792730
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer, PMID: 29355075
Nivolumab for the treatment of hepatocellular carcinoma, PMID: 30304963
Nivolumab for the treatment of hepatocellular carcinoma, PMID: 32249635
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression, PMID: 29884413
Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma, PMID: 30488824
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort, PMID: 31629915
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma, PMID: 30124333
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, PMID: 32673417
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153, PMID: 32910710
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial, PMID: 30659987
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience, PMID: 32507911
Cost-effectiveness of nivolumab in advanced melanoma: a drug review, PMID: 33225752
Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults, PMID: 31914172
An update on the safety of nivolumab for the treatment of advanced melanoma, PMID: 32293935
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study, PMID: 29570421
Nivolumab for the treatment of urothelial cancers, PMID: 29363363
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial, PMID: 32852531
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma, PMID: 32822275
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC, PMID: 29802888
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study, PMID: 31112476
Nivolumab: an investigational agent for the treatment of biliary tract cancer, PMID: 33307866
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer, PMID: 30215677
Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations, PMID: 32664269
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078), PMID: 33321441
Nivolumab in squamous cell carcinoma of the head and neck, PMID: 29560755
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab, PMID: 31638948
Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial, PMID: 31182249
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer, PMID: 29866947
Nivolumab-induced lichen planus, PMID: 31382865
Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study, PMID: 33219460
Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 30293207
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma, PMID: 29908324
Nivolumab-induced erosive pustular dermatosis of the scalp, PMID: 32516431
Nivolumab-induced toxic epidermal necrolysis with retiform purpura, PMID: 32281097
Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT, PMID: 32701815
Nivolumab for the Treatment of Advanced Pediatric Malignancies, PMID: 33288608
Activity of regorafenib plus nivolumab, PMID: 32398704
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141), PMID: 32583557
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153), PMID: 31121324
Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature, PMID: 31451458
Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature, PMID: 31647029
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study, PMID: 30642819
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14), PMID: 33188912
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types, PMID: 31959348
Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review, PMID: 32783492
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab, PMID: 29934411
[Nivolumab-induced hypothyroidism: A case report], PMID: 30837393
Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature, PMID: 32941716
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis, PMID: 33239030
For research use only. Not for human or drug use.
